UPCC 09618: Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
Enrolling By Invitation
99 years or below
All
Phase
2
63 participants needed
1 Location
Brief description of study
The main purpose of this study is to determine the rate of positive sentinel lymph nodes (i.e. the closest draining lymph node(s) to the primary melanoma site) and to test whether treatment with pembrolizumab before surgery to remove melanoma reduces the rate of positive sentinel lymph nodes in patients with stage IIB/C melanoma.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: melanoma
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 832023
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
